Company: CERO
Filing Date: 2025-08-11
Form Type: S-3
Source: 0001213900-25-073849
Chunk: 4

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-11
Form: S-3
Chunk 4
---
5, the closing price of our Common Stock was $8.10 per share and the closing price of our Public Warrants was $0.0114
per warrant.

We are an “emerging growth company” and a “smaller reporting company” under applicable federal securities laws and will be subject to reduced public company reporting requirements for so long as we remain an emerging growth company or a smaller reporting company.

Investing in our securities involves a high degree of risk. Before buying any securities, you should carefully read the discussion of the risks of investing in our securities in “Risk Factors” beginning on page 5 of this prospectus and any other risk factors contained in any applicable prospectus supplement and in the documents incorporated by reference herein and therein.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of the securities to be issued under this prospectus or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

<div align='center'>The date of this prospectus is , 2025.

TABLE OF CONTENTS</div>

|                                                      | Page |
| SELECTED DEFINITIONS                                 |   ii |
| CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS |   iv |
| ABOUT THIS PROSPECTUS                                |  iii |
| MARKET AND INDUSTRY INFORMATION                      |   vi |
| TRADEMARKS                                           |  vii |
| PROSPECTUS SUMMARY                                   |    1 |
| THE OFFERING                                         |    3 |
| INFORMATION RELATED TO OFFERED SECURITIES            |    4 |
| RISK FACTORS                                         |    5 |
| USE OF PROCEEDS                                      |    7 |
| SELLING STOCKHOLDERS                                 |    8 |
| PLAN OF DISTRIBUTION                                 |   11 |
| LEGAL MATTERS                                        |   13 |
| EXPERTS                                              |   13 |
| WHERE YOU CAN FIND MORE INFORMATION                  |   13 |
| INCORPORATION OF CERTAIN INFORMATION BY REFERENCE    |   14 |

<div align='center'>i

SELECTED DEFINITIONS</div>

As used in this prospectus,
unless otherwise noted or the context otherwise requires, references to the following capitalized terms have the meanings set forth below:

“Business Combination”
refers to the transactions contemplated by the Business Combination Agreement, including the merger between Merger Sub and Legacy CERo.

“Business Combination Agreement” refers to the Business Combination Agreement,